On May 5, 2026, Borui Pharmaceutical, an innovative drug company listed on the STAR Market, announced that its independently developed GLP-1/GIP dual receptor agonist—BGM0504 Injection—achieved positive topline results in a Phase III clinical study (Project No.: BGM0504-III-WL) designed to evaluate its efficacy and safety in overweight or obese subjects.
BGM0504 is a GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist independently developed by the company; it activates downstream pathways to elicit biological effects such as blood glucose control, weight loss, and the treatment of metabolic dysfunction-associated steatohepatitis (MASH).